| (Values in U.S. Thousands) | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 |
| Sales | 2,214,960 | 2,070,280 | 2,110,480 | 1,877,980 | 3,672,400 |
| Sales Growth | +6.99% | -1.90% | +12.38% | -48.86% | +0.22% |
| Net Income | 182,450 | 236,320 | 229,010 | 322,330 | 331,000 |
| Net Income Growth | -22.80% | +3.19% | -28.95% | -2.62% | +6.26% |
Tate & Lyle Plc S/Adr (TATYY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Tate & Lyle Ventures and Agri Investment Fund have co-led a 3.5m investment into Fugeia, a newly formed functional food technology business with a focus on gut health.
Fiscal Year End Date: 03/31